by Zumla A. Lancet Infect Dis, July 2002, 2:393.
Summary: Recent global partnership initiatives have focused on stimulating further interest in the development and provision of drugs for the world's top three killer infectious diseases: AIDS/HIV, malaria, and tuberculosis. The “most neglected” diseases (where there are no affordable, effective, easy to use medicines available) continue to cause significant morbidity and mortality in developing countries. This paper is a short introduction to a series of articles outlining research and development priorities for sleeping sickness, visceral leishmaniasis and malaria.
